The effects of hydrocortisone on rat heart muscarinic and adrenergic alpha 1, beta 1 and beta 2 receptors, propranolol-resistant binding sites and on some subsequent steps in intracellular signalling
Language English Country Germany Media print-electronic
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Receptors, Adrenergic drug effects metabolism physiology MeSH
- Receptors, Adrenergic, alpha-1 drug effects metabolism physiology MeSH
- Adrenergic beta-Antagonists pharmacology MeSH
- Receptors, Adrenergic, beta-1 drug effects metabolism physiology MeSH
- Receptors, Adrenergic, beta-2 drug effects metabolism physiology MeSH
- Receptors, Adrenergic, beta drug effects metabolism physiology MeSH
- Glucocorticoids administration & dosage pharmacology MeSH
- Hydrocortisone administration & dosage pharmacology MeSH
- Injections, Subcutaneous MeSH
- Rats MeSH
- Myocardium metabolism MeSH
- Rats, Wistar MeSH
- Propanolamines pharmacology MeSH
- Propranolol pharmacology MeSH
- Radioligand Assay MeSH
- Receptors, Muscarinic drug effects metabolism physiology MeSH
- Signal Transduction drug effects MeSH
- Heart Ventricles drug effects MeSH
- Binding Sites MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- adrenergic beta-4 receptor MeSH Browser
- Receptors, Adrenergic MeSH
- Receptors, Adrenergic, alpha-1 MeSH
- Adrenergic beta-Antagonists MeSH
- Receptors, Adrenergic, beta-1 MeSH
- Receptors, Adrenergic, beta-2 MeSH
- Receptors, Adrenergic, beta MeSH
- CGP 12177 MeSH Browser
- Glucocorticoids MeSH
- Hydrocortisone MeSH
- Propanolamines MeSH
- Propranolol MeSH
- Receptors, Muscarinic MeSH
Glucocorticoids affect the expression and density of neurotransmitter receptors in many tissues but data concerning the heart are contradictory and incomplete. We injected rats with hydrocortisone for 1-12 days and measured the densities of cardiac muscarinic receptors, alpha(1)-, beta(1)- and beta(2)-adrenoceptors and propranolol-resistant binding sites (formerly assumed to be the putative beta(4)-adrenoceptor). Some aspects of intracellular signalling were also evaluated: we measured adenylyl cyclase activity (basal, isoprenaline- and forskolin-stimulated and carbachol-inhibited), the coupling between muscarinic receptors and G proteins and basal and isoprenaline-stimulated heart rate. The density of cardiac muscarinic receptors increased (in both the atria and the ventricles). The density of beta(1)-adrenoceptors increased in the atria and was little changed in the ventricles. The density of beta(2)-adrenoceptors increased in both the atria and the ventricles. The number of alpha(1)-adrenoceptors decreased initially, followed by a transient increase in the atria and did not change in the ventricles. The density of propranolol-resistant binding sites first increased and then diminished in the atria and did not change in the ventricles. Although there were noticeable changes in receptor densities, the stimulatory and inhibitory effects on adenylyl cyclase, basal and isoprenaline-stimulated heart rate and the coupling between muscarinic receptors and G proteins were not significantly altered. This may indicate that changes in receptor densities might be one of the mechanisms maintaining stable functional output.
See more in PubMed
Mol Pharmacol. 2001 May;59(5):1029-36 PubMed
Am J Physiol. 1997 Apr;272(4 Pt 1):L745-51 PubMed
Mol Pharmacol. 1995 Feb;47(2):322-9 PubMed
Am J Physiol. 1993 May;264(5 Pt 1):E763-9 PubMed
J Physiol. 1993 Nov;471:41-60 PubMed
Can J Physiol Pharmacol. 2001 May;79(5):393-9 PubMed
Br J Pharmacol. 1996 Jan;117(1):210-6 PubMed
J Clin Invest. 1991 Aug;88(2):385-9 PubMed
Endocrinology. 1981 Feb;108(2):720-2 PubMed
Life Sci. 1998;63(13):1169-82 PubMed
Biochim Biophys Acta. 1983 Oct 4;760(1):77-83 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 2003 Jan;367 (1):10-21 PubMed
Br J Pharmacol. 1998 Feb;123(3):371-80 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):667-81 PubMed
Circ Res. 1999 Nov 26;85(11):1085-91 PubMed
Am J Respir Cell Mol Biol. 2001 Apr;24(4):485-91 PubMed
Biochem J. 1996 Aug 1;317 ( Pt 3):925-31 PubMed
Mol Pharmacol. 1999 Mar;55(3):497-507 PubMed
Am J Physiol Endocrinol Metab. 2001 Feb;280(2):E199-202 PubMed
Physiol Rev. 1999 Oct;79(4):1373-430 PubMed
Pharmacol Ther. 1993 Jun;58(3):319-79 PubMed
Trends Pharmacol Sci. 2000 Nov;21(11):426-31 PubMed
J Neurochem. 1999 Mar;72(3):900-9 PubMed
Anal Biochem. 1977 Dec;83(2):346-56 PubMed
Biochem J. 1994 Sep 1;302 ( Pt 2):397-403 PubMed
Circ Res. 1996 Jul;79(1):86-93 PubMed
J Biol Chem. 1998 Nov 27;273(48):32158-66 PubMed
Physiol Res. 2002;51(2):131-7 PubMed
J Dev Physiol. 1991 Dec;16(6):331-9 PubMed
Trends Pharmacol Sci. 2002 Apr;23(4):171-6 PubMed
Life Sci. 1996 May 24;58(26):2423-30 PubMed
Br J Pharmacol. 1989 Jul;97(3):691-700 PubMed
Endocr Rev. 2000 Feb;21(1):55-89 PubMed
J Cardiovasc Pharmacol. 1983 May-Jun;5(3):430-7 PubMed
J Biol Chem. 1990 Apr 5;265(10 ):5370-5 PubMed
Fundam Clin Pharmacol. 1997;11(2):111-6 PubMed
Endocrinology. 1981 Mar;108(3):977-80 PubMed
Mol Pharmacol. 1993 Dec;44(6):1085-93 PubMed
Mol Cell Endocrinol. 2001 Jul 5;181(1-2):165-78 PubMed
Endocrinology. 1980 Nov;107(5):1646-8 PubMed
J Biol Chem. 1988 Sep 25;263(27):13557-63 PubMed
Circ Res. 1999 Nov 26;85(11):1101-11 PubMed
J Biol Chem. 1988 Jul 5;263(19):9067-70 PubMed
Gen Pharmacol. 1994 Nov;25(7):1341-7 PubMed
Mol Pharmacol. 1998 Dec;54(6):1016-23 PubMed
Allosteric Modulation of Muscarinic Receptors by Cholesterol, Neurosteroids and Neuroactive Steroids
The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles
